Advertisement
Australia markets closed
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • AUD/USD

    0.6418
    -0.0008 (-0.12%)
     
  • OIL

    83.24
    +0.51 (+0.62%)
     
  • GOLD

    2,407.30
    +9.30 (+0.39%)
     
  • Bitcoin AUD

    100,061.27
    +1,403.38 (+1.42%)
     
  • CMC Crypto 200

    1,383.48
    +70.86 (+5.40%)
     
  • AUD/EUR

    0.6022
    -0.0008 (-0.14%)
     
  • AUD/NZD

    1.0901
    +0.0026 (+0.24%)
     
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NASDAQ

    17,005.71
    -388.61 (-2.23%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • Dow Jones

    37,946.59
    +171.21 (+0.45%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Global Liver Cirrhosis Markets, Epidemiology and Patient Flow Report 2020-2035

Dublin, May 18, 2021 (GLOBE NEWSWIRE) -- The "Global Liver Cirrhosis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Global Liver Cirrhosis Epidemiology and Patient Flow Analysis - 2021, provides Liver Cirrhosis epidemiology, demographics, and patient flow. The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.

The research provides population data to characterize Liver Cirrhosis patients, history of the disease at the population level (Liver Cirrhosis prevalence, Liver Cirrhosis incidence) and at the clinical level (from diagnosis to treated patients). It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.

Research scope:

  • Liver Cirrhosis patient flow: Liver Cirrhosis prevalence, diagnosed, and drug-treated patients

  • Countries: US, Germany, France, Italy, Spain, UK, Japan, G7 Countries

  • Demographics: Liver Cirrhosis patients by age group, gender

  • Forecast: Liver Cirrhosis epidemiology forecast to 2035

The data from this research will help executives:

  • Establish basis for Liver Cirrhosis market sizing, assessing market potential, and developing drug forecast models

  • Identify Liver Cirrhosis patients segments through age groups, gender, and disease sub-types

  • Develop Liver Cirrhosis population-based health management frameworks

  • Evaluate Liver Cirrhosis market opportunities, identify target patient population

  • Align marketing decisions with the Liver Cirrhosis target population

  • Communicate leadership and health authorities about your Liver Cirrhosis target patient population

ADVERTISEMENT

Key Topics Covered:

1. Research Methodology
2. Liver Cirrhosis Patients Definition
3. US Liver Cirrhosis Epidemiology and Patient Flow
4. Germany Liver Cirrhosis Epidemiology and Patient Flow
5. France Liver Cirrhosis Epidemiology and Patient Flow
6. Italy Liver Cirrhosis Epidemiology and Patient Flow
7. Spain Liver Cirrhosis Epidemiology and Patient Flow
8. UK Liver Cirrhosis Epidemiology and Patient Flow
9. Europe Liver Cirrhosis Epidemiology and Patient Flow
10. Japan Liver Cirrhosis Epidemiology and Patient Flow
11. Global Liver Cirrhosis Epidemiology and Patient Flow

For more information about this report visit https://www.researchandmarkets.com/r/tcba2c

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900